GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes By Ogkologos - July 13, 2026 156 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large real-world cohort Source RELATED ARTICLESMORE FROM AUTHOR Two novel bispecific antibodies in combination with chemotherapy show efficacy in neuroendocrine carcinomas Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell lung cancer Adding Abiraterone to ADT and Docetaxel Improves Survival in Metastatic Prostate Cancer MOST POPULAR Stressed out – the cancer cells that survive chemotherapy, but at... April 29, 2021 A radical project: video game design meets cancer research December 1, 2022 Breast Cancer Patient Takes Silly Pictures During Each Radiation Treatment to... March 25, 2021 Maintenance Therapy Delays Cancer Growth for People With Advanced or Recurrent... July 24, 2023 Load more HOT NEWS FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for... Neoadjuvant Followed by Adjuvant Pembrolizumab Prolongs Event-Free Survival Compared to Adjuvant... Topical Diclofenac Gel Reduces the Incidence of Hand-Foot Syndrome in Patients... Neoadjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy Can Be Delivered Safely in Patients with Operable...
